)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Aerovate Therapeutics
Aerovate Therapeutics (AVTE) investor relations material
Aerovate Therapeutics has been delisted
Aerovate Therapeutics Q1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2025 earnings summary25 Apr, 2025
Executive summary
Halted all development of AV-101 after negative Phase 2b results; no plans to resume R&D or develop new products.
Entered into a merger agreement with Jade Biosciences; merger approved by shareholders and pending closing.
Declared a special cash dividend of $69.6 million ($2.40/share) contingent on merger closing.
Implemented a workforce reduction plan, terminating 92% of staff, incurring $6.5 million in one-time severance costs.
Company will become a holding entity for Jade's business post-merger; Aerovate shareholders will own ~1.6% of the combined company.
Financial highlights
Net loss for Q1 2025 was $2.5 million, a significant improvement from $23.2 million in Q1 2024.
No revenue generated; all product development discontinued.
Cash and cash equivalents plus short-term investments totaled $76.2 million as of March 31, 2025.
Operating expenses dropped to $3.4 million in Q1 2025 from $24.6 million in Q1 2024, reflecting the wind-down of R&D.
Net cash used in operating activities was $2.4 million in Q1 2025, down from $23.7 million in Q1 2024.
Outlook and guidance
Existing cash and investments expected to fund operations for at least 12 months while completing the merger.
No plans to resume AV-101 or initiate new product development; future operations depend on merger outcome.
If merger fails, board may pursue dissolution and liquidation, with cash available for distribution dependent on timing and liabilities.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Aerovate Therapeutics
- Halted AV-101, cut workforce, and agreed to merge with Jade; future hinges on deal closure.AVTE
Q3 2024 - Development halted, strategic review underway, and major cost reductions implemented.AVTEQ2 2024
- Aerovate ended AV-101 development, cut staff, and agreed to merge with Jade, pending shareholder approval.AVTEQ4 2024
Aerovate Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases. The company's lead product candidate is AV-101, a dry powder inhaled formulation of imatinib, designed to treat pulmonary arterial hypertension (PAH). This formulation aims to deliver the drug directly to the lungs, targeting the underlying disease mechanisms while minimizing systemic side effects. Aerovate Therapeutics is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.